论文部分内容阅读
Src是非受体型酪氨酸激酶家族成员之一,通过广泛的信号转导通路参与HP感染、胃癌细胞粘附、受体调节、增殖和血管形成等。近年来研究表明,Src在胃癌组织中异常表达或活性增高,与胃癌的发生发展密切相关。因此,研究Src和胃癌的关系有着重要意义。目前,针对Src的靶向抑制剂已经进入临床试验。大量研究发现,Src抑制剂包括Dasatinib、AZD0530、Sunitinib等对胃癌有抑制作用,这将为胃癌的治疗开辟新的治疗途径。
Src, a member of the non-receptor tyrosine kinase family, is involved in HP infection, gastric cancer cell adhesion, receptor regulation, proliferation and angiogenesis through a wide range of signal transduction pathways. In recent years, studies have shown that Src in gastric cancer abnormal expression or activity increased, closely related with the occurrence and development of gastric cancer. Therefore, the study of Src and gastric cancer is of great significance. Currently, targeted inhibitors of Src have entered clinical trials. A large number of studies found that Src inhibitors, including Dasatinib, AZD0530, Sunitinib and other gastric cancer inhibition, which will open up a new therapeutic approach for the treatment of gastric cancer.